Prostatype Genomics publishes Annual Report for 2019/20

About Prostatype Genomics


Prostatype Genomics AB manufactures, markets and sells the prognostic gene test
Prostatype®. By giving a assessment of the aggressiveness of the prostate cancer,
Prostatype® helps clinicians and patients to make correct treatment decisions.
Over and under treatment of prostate cancer can be minimized, the quality of life for
the patient improved and money can be saved for the health care sector.

This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 17-05-2021 09:00 CET.

A Message from Prostatype Genomics AB Regarding COVID-19. In response to the COVID-19 outbreak the World Health Organization (WHO) declared a pandemic on Wednesday 11th March 2020.